eligibility_summary
Adults (≥18) with advanced/metastatic solid tumors with high CCR8, ECOG ≤1, measurable disease, prior standard therapy or no options, and no prior CCR8 tx. Provide tumor tissue, some cohorts need on‑treatment biopsy. Contraception required, FCBP negative pregnancy test. Exclude active leptomeningeal or untreated brain mets, active/relapsing autoimmune, ILD/pneumonitis or uncontrolled lung disease, prior grade 3 irAEs, HBV DNA ≥500 IU/mL, active HCV, HIV unless treated per criteria, recent PE/MI/HF, uncontrolled diabetes.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions and mechanisms: • BGB-A3055: investigational monoclonal antibody immunotherapy targeting CCR8. Designed to bind CCR8 (chemokine receptor) enriched on intratumoral regulatory T cells (Tregs), promoting Fc-mediated depletion of CCR8+ Tregs and/or blocking CCR8–CCL1 signaling to reduce immunosuppression. • Tislelizumab (BGB‑A317): anti–PD‑1 monoclonal antibody immune‑checkpoint inhibitor that blocks PD‑1 to restore effector T‑cell activation. • Chemotherapy (optional in expansion): standard cytotoxic agents per guidelines. Cells/pathways targeted: • CCR8+ regulatory T cells within the tumor microenvironment (TME). • PD‑1 checkpoint pathway on T cells. Overall strategy: deplete suppressive Tregs (CCR8) and release PD‑1 inhibition to enhance antitumor T‑cell responses in advanced/metastatic solid tumors.